Melanoma News

CancerConnect melanoma news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of melanoma research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of melanoma treatment and survivorship.

Share

Melanoma News


3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma (July 21, 2016)

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing... Continue Reading

Check It Out: May is Skin Cancer Awareness Month (May 3, 2016)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around... Continue Reading

NLN Update on the Lymphedema Treatment Act (March 16, 2016)

Updated March 2016 2016 may well be the year that Congress votes to approve the Lymphedema Treatment Act, which provides a Medicare benefit category for essential compression garments and supplies needed... Continue Reading

Year in Review: Melanoma (February 24, 2016)

After several years of exciting developments in melanoma therapy, progress continued throughout 2015 with FDA approved PD-1 immunotherapy treatments and the first-ever approved oncolytic virus therapy... Continue Reading

Patients With Early-Stage Melanoma And Lung Cancer Among Those Standing To Benefit From Immunotherapy (January 29, 2016)

Excerpted from: Advances in Cancer Research And Treatment: 2015 Year In Review Immunotherapy, a type of biological therapy, is among the most promising areas of cancer treatment advances. This approach... Continue Reading

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma (December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which... Continue Reading

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma (November 9, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer,... Continue Reading

Imlygic® Approved for Melanoma (October 28, 2015)

Imlygic® (talimogene laherparepvec), the first ever FDA-approved oncolytic virus therapy, has been approved for the treatment of melanoma. The approval is for the treatment of melanoma sites in the skin... Continue Reading

MRA Hails FDA Approval of First Combination Immunotherapy for Melanoma (October 1, 2015)

The Melanoma Research Alliance (MRA) welcomes the U.S. Food and Drug Administration (FDA) decision to approve the use of Bristol-Myers Squibb’s (BMS) nivolumab (Opdivo®) and ipilimumab (Yervoy®) in... Continue Reading

More Melanoma News

Latest Melanoma News By Stage


Screening/Prevention

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced... Continue Reading

Check It Out: May is Skin Cancer Awareness Month (May 3, 2016)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Melanoma Support Community: Information, Support, Hope (September 30, 2015)

  Post questions, comment on discussions and find support about living with melanoma by signing up for CancerConnect’s Melanoma Community. Registering with CancerConnect is fast, free and confidential. To register go to http://cancerconnect.com/register/,... Continue Reading

National Melanoma Awareness Month on CancerConnect (May 1, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of melanoma educational programs for national melanoma awareness month. As the month of May brings melanoma into focus, it’s time to increase public understanding... Continue Reading

Melanoma Research Alliance Reports Wendy Selig to Step Down as President and CEO (February 9, 2015)

CancerConnect News:  The Melanoma Research Alliance (“MRA”) announced today that Wendy Selig has informed its Board of Directors of her plan to step down as President and CEO, posts she has held for the past five years, in order to establish a new... Continue Reading

More Screening and Prevention

Stages I-II

Check It Out: May is Skin Cancer Awareness Month (May 3, 2016)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Melanoma Support Community: Information, Support, Hope (September 30, 2015)

  Post questions, comment on discussions and find support about living with melanoma by signing up for CancerConnect’s Melanoma Community. Registering with CancerConnect is fast, free and confidential. To register go to http://cancerconnect.com/register/,... Continue Reading

National Melanoma Awareness Month on CancerConnect (May 1, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of melanoma educational programs for national melanoma awareness month. As the month of May brings melanoma into focus, it’s time to increase public understanding... Continue Reading

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the use of BRAF inhibitors and the long awaited PD-1 immunotherapy... Continue Reading

Yervoy® May be Beneficial in Uveal Melanoma (December 8, 2014)

CancerConnect News:The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented at the recent Society of Melanoma Research (SMR)... Continue Reading

More Stages I-II

Stage III

Check It Out: May is Skin Cancer Awareness Month (May 3, 2016)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma (December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The... Continue Reading

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma (November 9, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer, as it is more likely than other forms of skin... Continue Reading

MRA Hails FDA Approval of First Combination Immunotherapy for Melanoma (October 1, 2015)

The Melanoma Research Alliance (MRA) welcomes the U.S. Food and Drug Administration (FDA) decision to approve the use of Bristol-Myers Squibb’s (BMS) nivolumab (Opdivo®) and ipilimumab (Yervoy®) in combination as a treatment for patients with unresectable... Continue Reading

Melanoma Support Community: Information, Support, Hope (September 30, 2015)

  Post questions, comment on discussions and find support about living with melanoma by signing up for CancerConnect’s Melanoma Community. Registering with CancerConnect is fast, free and confidential. To register go to http://cancerconnect.com/register/,... Continue Reading

More Stage III

Stage IV

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma (July 21, 2016)

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were... Continue Reading

Check It Out: May is Skin Cancer Awareness Month (May 3, 2016)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma (December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The... Continue Reading

MRA Hails FDA Approval of First Combination Immunotherapy for Melanoma (October 1, 2015)

The Melanoma Research Alliance (MRA) welcomes the U.S. Food and Drug Administration (FDA) decision to approve the use of Bristol-Myers Squibb’s (BMS) nivolumab (Opdivo®) and ipilimumab (Yervoy®) in combination as a treatment for patients with unresectable... Continue Reading

Melanoma Support Community: Information, Support, Hope (September 30, 2015)

  Post questions, comment on discussions and find support about living with melanoma by signing up for CancerConnect’s Melanoma Community. Registering with CancerConnect is fast, free and confidential. To register go to http://cancerconnect.com/register/,... Continue Reading

More Stage IV

Recurrent

Check It Out: May is Skin Cancer Awareness Month (May 3, 2016)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma (November 9, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer, as it is more likely than other forms of skin... Continue Reading

Melanoma Support Community: Information, Support, Hope (September 30, 2015)

  Post questions, comment on discussions and find support about living with melanoma by signing up for CancerConnect’s Melanoma Community. Registering with CancerConnect is fast, free and confidential. To register go to http://cancerconnect.com/register/,... Continue Reading

President Jimmy Carter Will Undergo Treatment for Melanoma (August 20, 2015)

Former President Jimmy Carter has melanoma and will begin undergoing radiation treatment today for four melanoma tumors in his brain, he told reporters at the Carter Center in Atlanta. Skin cancer is the most common form of cancer in the United States,... Continue Reading

New Combination Treatment Effective Against Melanoma Skin Metastases (August 18, 2015)

In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown. Led by Emanual Maverakis of the UC Davis Department of Dermatology,... Continue Reading

More Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS